Report from India - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Report from India
As biologic-drug patents move toward expiration in the US, Indian firms with experience in the follow-on biologics arena are eager to partner with global manufacturers and secure their place in the growing biosimilars market.

Pharmaceutical Technology
Volume 35, Issue 2, pp. 18-22

Accounting for regulatory delays

Kamal K. Sharma, managing director of Mumbai-based Lupin, says "Once clarity emerges on the regulatory front, especially in the US, biosimilar drugs could provide a huge potential. However, data exclusivity in the US market [remains] a severe challenge," said. The company expects to launch its first follow-on biologic product in India this year.

According to the research firm Nomura Equity Research, between 2008 and 2015, biopharmaceuticals worth $59 billion are set to lose patent protection globally. From 2012, the follow-on biologics market is expected to add an estimated $10 billion in incremental revenues each year until 2020. In the US, the Congressional Budget Office recently estimated that potential savings on biologic drug products in the US between 2009 and 2014 could be as high as $25 billion, once a pathway for approval and marketing follow-ons is implemented. The fact is, although some of the drugs targeted for follow-on versions have garnered billions of dollars in sales for the original manufacturers, cashing in for Indian companies would be "no walk in the park," says Cipla's Hamied. Much rests on the implementation of the follow-on biologics pathway in the US.

While the US sorts out its implementation plan, some Indian firms are focusing on Europe in the short term. For example, Biocon's Shaw said the firm is in the process of registering its insulin for the European market and has licensed its G-CSF (granulocyte colony stimulating factor) to a North American firm and to Abraxis BioScience for the European market. Biocon is in the midst of setting up a marketing office in London, making Europe its focus during the next 12 months.

Ranjit Kapadia, vice-president of the institutional research firm HDFC Securities in Mumbai, adds that, because the "US law will take a while to be implemented and could undergo some revisions, Indian companies will not be able to launch their biosimilar anytime soon. And that is why the Biocon deal with Pfizer makes perfect sense. They have sold the rights to Pfizer. Now, Pfizer will have to fight to market their biosimilars in the US, whereas the Indian firm can sit pretty."

A. Nair is a freelance writer based in Mumbai.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here